MMJ Phytotech Ltd., of Perth, Australia, said its Israeli subsidiary, Phytotech Therapeutics Ltd., received Helsinki and Ministry of Health approvals to conduct a phase II study of PTL-201 capsules in treating spasticity-related symptoms of multiple sclerosis (MS).